Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 20

recruiting
3 972
countries
28
conditions
2 103

467 trials match your criteria

Hodgkin's disease refractory+1

Not recruiting

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin

Metastatic malignant melanoma

Not recruiting

Study on the Effectiveness of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin

Squamous cell carcinoma of head and neck

Not recruiting

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Metastatic malignant melanoma

Not recruiting

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1607

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Breast cancer+4

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Neuroendocrine carcinoma of the skin+4

Not recruiting

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BT-001

Oesophageal carcinoma

Not recruiting

Study of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer

Not recruiting

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Kaposi's sarcoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Classic Kaposi Sarcoma After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Neoplasm

Not recruiting

Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ANV600

Non-small cell lung cancer+1

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.